Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Dedicated

- PMLiVE

GSK announces positive late-stage results for IL-5 inhibitor Nucala in COPD

The chronic respiratory disease affects more than 300 million people globally

- PMLiVE

Pfizer/Valneva share promising results for Lyme disease vaccine candidate

There are currently no approved human vaccines for the bacterial infection

- PMLiVE

Eli Lilly and HAYA Therapeutics enter metabolic condition partnership worth $1bn

The companies will aim to discover regulatory genome targets for obesity and related metabolic conditions

- PMLiVE

Worldwide Clinical Trials appoints Alessandra Vignola as president of cardiovascular and metabolic

Vignola has more than 30 years of experience in the pharmaceutical and clinical research industry

- PMLiVE

New Origins Webinar – ” Why Patient Perspectives Matter: Driving Success in Clinical Trials”

Origins are pleased to announce the first instalment of our Autumn/Winter webinar series! Join us on Tuesday 15th October at 2pm BST as we discuss " Why Patient Perspectives Matter:...

Origins – The Patient Focused Specialists

- PMLiVE

MSD’s Welireg recommended by NICE to treat rare von Hippel-Lindau disease

Approximately one in every 70,000 people are affected by the tumour-causing genetic disease

- PMLiVE

MHRA authorises first in new class of treatment for endometriosis symptoms

The chronic condition affects approximately 176 million women worldwide

Biogen Idec building

Biogen shares promising results for higher dose nusinersen in spinal muscular atrophy

The neuromuscular disease affects approximately one in every 10,000 babies worldwide

- PMLiVE

Unlocking market access success for cell and gene therapies: the vital role of early strategic planning

By Manca Povsic

Amiculum

- PMLiVE

Novartis’ Fabhalta recommended by NICE to treat rare blood disorder PNH

Paroxysmal nocturnal haemoglobinuria affects approximately ten to 20 people per million worldwide

- PMLiVE

Moderna’s JN.1-adapted COVID-19 vaccine approved by MHRA for adults and children

The JCVI has already advised the UK government on eligible groups for this year’s autumn vaccination programme

- PMLiVE

Roche shares positive 48-week results for investigational BTK inhibitor in relapsing MS

Approximately 2.9 million people worldwide are affected by the neurological disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links